Plasma Pyrophosphate and Vascular Calcification in Chronic Kidney Disease

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2009 Jul 28

PMID 19633093

Citations 68

Authors

W Charles ONeill

Mhairi K Sigrist

Christopher W McIntyre

Affiliations

Soon will be listed here.

Abstract

Background: Pyrophosphate (PPi) is a potent inhibitor of vascular calcification and may be deficient in renal failure. We sought to determine whether plasma PPi is affected by dialysis or the mode of dialysis and whether it correlates with vascular calcification.

Methods: PPi was measured in plasma samples stored from a recent study of vascular calcification in 54 HD patients, 23 peritoneal dialysis (PD) patients and 38 patients with stage 4 chronic kidney disease (CKD). Calcification was quantified in a standardized section of the superficial femoral artery using computed tomography, and PPi was measured by enzyme assay, at both baseline and 1 year.

Results: Baseline plasma PPi was weakly correlated with age and serum phosphate, but not with alkaline phosphatase activity or other biochemical parameters, and did not differ between HD, PD and CKD patients. Both baseline calcification score and change in the calcification score at 1 year decreased with increasing quartiles of plasma PPi. In a multivariate analysis, plasma PPi was independently correlated with baseline calcification (P = 0.039) and the change in calcification (P = 0.029).

Conclusion: Plasma PPi is negatively associated with vascular calcification in end-stage renal disease (ESRD) and CKD but is not affected by dialysis, the mode of dialysis or nutritional or inflammatory status. Although these data are consistent with an inhibitory effect of PPi on vascular calcification, further studies are needed to establish a causal role.

Citing Articles

Phosphate in Cardiovascular Disease: From New Insights Into Molecular Mechanisms to Clinical Implications.

Turner M, Beck L, Hill Gallant K, Chen Y, Moe O, Kuro-O M Arterioscler Thromb Vasc Biol. 2024; 44(3):584-602.

PMID: 38205639 PMC: 10922848. DOI: 10.1161/ATVBAHA.123.319198.

The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia.

Hidaka N, Murata H, Tachikawa K, Osaki K, Sekiyama T, Kinoshita Y JBMR Plus. 2023; 7(12):e10842.

PMID: 38130758 PMC: 10731098. DOI: 10.1002/jbm4.10842.

Humoral and cellular factors inhibit phosphate-induced vascular calcification during the growth period.

Kamei Y, Okumura Y, Adachi Y, Mori Y, Sakai M, Ohnishi K J Clin Biochem Nutr. 2023; 73(3):198-204.

PMID: 37970550 PMC: 10636584. DOI: 10.3164/jcbn.23-11.

ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency.

Ferreira C, Carpenter T, Braddock D Annu Rev Pathol. 2023; 19:507-540.

PMID: 37871131 PMC: 11062289. DOI: 10.1146/annurev-pathmechdis-051222-121126.

Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification.

Dai Z, Zhang X J Cardiovasc Dev Dis. 2023; 10(5).

PMID: 37233174 PMC: 10218918. DOI: 10.3390/jcdd10050207.

References

Rachow J, Ryan L . Inorganic pyrophosphate metabolism in arthritis. Rheum Dis Clin North Am. 1988; 14(2):289-302. View

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

Sigrist M, Taal M, Bungay P, McIntyre C . Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2(6):1241-8. DOI: 10.2215/CJN.02190507. View

Luo G, Ducy P, McKee M, Pinero G, Loyer E, Behringer R . Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386(6620):78-81. DOI: 10.1038/386078a0. View

Block G, Spiegel D, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A . Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68(4):1815-24. DOI: 10.1111/j.1523-1755.2005.00600.x. View

Lomashvili K, Garg P, Narisawa S, Millan J, ONeill W . Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008; 73(9):1024-30. PMC: 3010853. DOI: 10.1038/ki.2008.26. View

Meyer J . Can biological calcification occur in the presence of pyrophosphate?. Arch Biochem Biophys. 1984; 231(1):1-8. DOI: 10.1016/0003-9861(84)90356-4. View

Silcox D, McCarty D . Measurement of inorganic pyrophosphate in biological fluids. Elevated levels in some patients with osteoarthritis, pseudogout, acromegaly, and uremia. J Clin Invest. 1973; 52(8):1863-70. PMC: 302467. DOI: 10.1172/JCI107369. View

Chertow G, Burke S, Raggi P . Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62(1):245-52. DOI: 10.1046/j.1523-1755.2002.00434.x. View

10.

Stompor T, Pasowicz M, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K . Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis. 2004; 44(3):517-28. View

11.

ONeill W . The fallacy of the calcium-phosphorus product. Kidney Int. 2007; 72(7):792-6. DOI: 10.1038/sj.ki.5002412. View

12.

Sigrist M, Bungay P, Taal M, McIntyre C . Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant. 2005; 21(3):707-14. DOI: 10.1093/ndt/gfi236. View

13.

Lomashvili K, Khawandi W, ONeill W . Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005; 16(8):2495-500. DOI: 10.1681/ASN.2004080694. View

14.

Lomashvili K, Cobbs S, Hennigar R, Hardcastle K, ONeill W . Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol. 2004; 15(6):1392-401. DOI: 10.1097/01.asn.0000128955.83129.9c. View

15.

Coburn S, Mahuren J, Jain M, Zubovic Y, Wortsman J . Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate. J Clin Endocrinol Metab. 1998; 83(11):3951-7. DOI: 10.1210/jcem.83.11.5288. View

16.

Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte P . PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001; 158(2):543-54. PMC: 1850320. DOI: 10.1016/S0002-9440(10)63996-X. View

17.

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

18.

Chertow G, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke S . Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004; 19(6):1489-96. DOI: 10.1093/ndt/gfh125. View

19.

Farley J . Apoptosis may determine the release of skeletal alkaline phosphatase activity from human osteoblast-line cells. Calcif Tissue Int. 2002; 68(1):43-52. DOI: 10.1007/BF02685002. View

20.

Blacher J, Guerin A, Pannier B, Marchais S, London G . Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38(4):938-42. DOI: 10.1161/hy1001.096358. View